INSMED INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.05 USD | -3.39% |
|
+150.23% | +77.64% |
| May. 31 | Stifel Adjusts Price Target on Insmed to $67 From $39, Maintains Buy Rating | MT |
| May. 31 | Insmed Insider Sold Shares Worth $1,362,075, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,134 | 3,391 | 3,224 | 2,707 | 4,433 | 9,184 | - | - |
| Enterprise Value (EV) 1 | 2,003 | 3,231 | 3,089 | 2,863 | 4,993 | 9,677 | 9,699 | 9,779 |
| P/E ratio | -7.93 x | -11.1 x | -7.02 x | -5.11 x | -5.8 x | -12.6 x | -14.2 x | -23.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.6 x | 20.6 x | 17.1 x | 11 x | 14.5 x | 25.9 x | 17.7 x | 10.8 x |
| EV / Revenue | 14.7 x | 19.6 x | 16.4 x | 11.7 x | 16.4 x | 27.3 x | 18.7 x | 11.5 x |
| EV / EBITDA | -8.9 x | -12.9 x | -8.58 x | -6.4 x | -7.14 x | -14.9 x | -15.1 x | -24 x |
| EV / FCF | -6.84 x | -14.3 x | -8.34 x | -6.98 x | -9.09 x | -15.1 x | -16.1 x | -34 x |
| FCF Yield | -14.6% | -6.98% | -12% | -14.3% | -11% | -6.61% | -6.22% | -2.94% |
| Price to Book | 8.18 x | 12.4 x | 6.82 x | 30.8 x | -13.1 x | 124 x | 127 x | 404 x |
| Nbr of stocks (in thousands) | 89,344 | 101,868 | 118,372 | 135,477 | 143,062 | 161,182 | - | - |
| Reference price 2 | 23.88 | 33.29 | 27.24 | 19.98 | 30.99 | 56.98 | 56.98 | 56.98 |
| Announcement Date | 2/25/20 | 2/25/21 | 2/17/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 136.5 | 164.4 | 188.5 | 245.4 | 305.2 | 354.8 | 517.7 | 853.1 |
| EBITDA 1 | -225.1 | -251.1 | -359.8 | -447 | -699 | -650.3 | -640.7 | -406.9 |
| EBIT 1 | -235.2 | -265.2 | -375.1 | -457.3 | -709.6 | -650.7 | -592.8 | -374.1 |
| Operating Margin | -172.38% | -161.32% | -199.03% | -186.39% | -232.51% | -183.41% | -114.5% | -43.85% |
| Earnings before Tax (EBT) 1 | -253.6 | -292.7 | -436.4 | -480.2 | -747 | -703.3 | -663.9 | -433.5 |
| Net income 1 | -254.3 | -294.1 | -434.7 | -481.5 | -749.6 | -706.1 | -659.3 | -433.7 |
| Net margin | -186.37% | -178.87% | -230.63% | -196.26% | -245.59% | -199.01% | -127.34% | -50.84% |
| EPS 2 | -3.010 | -3.010 | -3.880 | -3.910 | -5.340 | -4.515 | -4.026 | -2.466 |
| Free Cash Flow 1 | -292.9 | -225.6 | -370.6 | -410.3 | -549.5 | -640 | -603.4 | -287.7 |
| FCF margin | -214.64% | -137.21% | -196.64% | -167.23% | -180.05% | -180.38% | -116.55% | -33.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/25/21 | 2/17/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 56.12 | 53.11 | 65.22 | 67.73 | 59.3 | 65.21 | 77.23 | 79.07 | 83.69 | 75.5 | 88.33 | 92.2 | 97.14 | - | - |
| EBITDA 1 | -95.43 | -87.28 | -86.1 | -125.6 | -148 | -145.6 | -233 | -144.9 | -175.5 | - | -166.6 | -167.3 | -171.6 | - | - |
| EBIT 1 | -99.08 | -89.83 | -88.32 | -127.7 | -151.5 | -148.2 | -235.5 | -147.7 | -178.3 | -145.5 | -164.1 | -166.4 | -180.7 | - | - |
| Operating Margin | -176.53% | -169.15% | -135.41% | -188.54% | -255.44% | -227.19% | -304.97% | -186.75% | -213.01% | -192.72% | -185.82% | -180.5% | -186.03% | - | - |
| Earnings before Tax (EBT) 1 | -113 | -94.24 | -95.14 | -130.8 | -160 | -159.3 | -244.3 | -158.4 | -185.1 | -156.5 | -174.6 | -175.9 | -185.7 | - | - |
| Net income 1 | -113 | -94.62 | -95.64 | -131.1 | -160.1 | -159.8 | -244.8 | -158.9 | -186.1 | -157.1 | -173.6 | -175.5 | -190.6 | - | - |
| Net margin | -201.3% | -178.17% | -146.65% | -193.63% | -270.02% | -244.98% | -316.99% | -201% | -222.31% | -208.07% | -196.56% | -190.37% | -196.21% | - | - |
| EPS 2 | -0.9500 | -0.8000 | -0.8000 | -1.090 | -1.210 | -1.170 | -1.780 | -1.110 | -1.280 | -1.060 | -1.120 | -1.109 | -1.197 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/17/22 | 5/5/22 | 8/4/22 | 10/27/22 | 2/23/23 | 5/4/23 | 8/3/23 | 10/26/23 | 2/22/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 156 | 560 | 493 | 515 | 594 |
| Net Cash position 1 | 130 | 161 | 135 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.3486 x | -0.8004 x | -0.7582 x | -0.8041 x | -1.461 x |
| Free Cash Flow 1 | -293 | -226 | -371 | -410 | -550 | -640 | -603 | -288 |
| ROE (net income / shareholders' equity) | -108% | -109% | -127% | -193% | - | - | -709% | -205% |
| ROA (Net income/ Total Assets) | - | - | -42.6% | -33.2% | -50.2% | -55.5% | -63.1% | -40.2% |
| Assets 1 | - | - | 1,020 | 1,450 | 1,493 | 1,273 | 1,045 | 1,079 |
| Book Value Per Share 2 | 2.920 | 2.680 | 3.990 | 0.6500 | -2.360 | 0.4600 | 0.4500 | 0.1400 |
| Cash Flow per Share 2 | - | -2.250 | -3.240 | -3.250 | -3.820 | -2.960 | -2.190 | - |
| Capex 1 | 42.3 | 6.24 | 7.29 | 9.88 | 13.3 | 12.9 | 13.2 | 14 |
| Capex / Sales | 30.97% | 3.8% | 3.87% | 4.03% | 4.35% | 3.62% | 2.55% | 1.64% |
| Announcement Date | 2/25/20 | 2/25/21 | 2/17/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
56.98
USD
Average target price
60.62
USD
Spread / Average Target
+6.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +77.64% | 9.19B | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- INSM Stock
- Financials Insmed Incorporated
